← Events of the day
Merck's sac-TMT significantly cuts death risk in endometrial cancer
🇺🇸 United States · Technology · 10 h ago
0 / 0 / 4
mentions in 1 / 6 / 24 h
0×
pace of the last 6 h vs the previous 18
26.10 15:40 UTC
first publication
Confirmed facts
Each fact is a sentence from a source that at least two independent outlets report.
Merck is developing the drug with Chinese biotech firm Kelun-Biotech, which discovered the therapy.
Sac-TMT reportedly cut death risk by one-third in advanced endometrial cancer trial
Estimated read time: 2-3 minutes Oct 26 — The US health regulator has accepted Merck's experimental targeted drug for a priority review based on data from a late-stage trial where it extended survival in women with an advanced form of endometrial cancer.
The drug, sacituzumab tirumotecan, also known as sac-TMT, delivers a cancer-killing payload to cells that carry a protein called TROP2, which is common in endometrial tumors.
A regulatory decision is expected by June 2027, Merck said.
Full evidence via the API
Facts with links, quotes, contradictions, unknowns, changes between versions and a suggested text length. On the Business plan there is a refined layer: Claude turns the sources into atomic facts with verbatim quotes and a short summary.
How it works
Pricing
Sources
The same group number means one site, one wire agency or a near-verbatim reprint: such articles count as one independent source.
Report an error